Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

9.675 -0.285 (-2.86%)
Streaming Delayed Price Updated: 12:30 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
These stocks may not be for everyone, but income-seekers might find what they're looking for in them. 
Via The Motley Fool
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,  
Via Benzinga
Topics Intellectual Property
Viatris Stock: Bear vs. Bull
This is a case where both sides have compelling arguments. 
Via The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Where Will Viatris Be in 5 Years?
Can this become a good growth business to invest in? 
Via The Motley Fool
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
The company is retaining the rights to specific over-the-counter drugs in some markets. 
Via Investor's Business Daily
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
Viatris Inc (NASDAQ: VTRS) disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by  
Via Benzinga
Could Viatris Stock Help You Become a Millionaire?
Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment? 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to... 
Via Benzinga
2 Beaten-Down Dividend Stocks to Buy
These two stocks look like bargains right now for income investors. 
Via The Motley Fool
Is Viatris Stock Good for Dividend Income?
If you keep your expectations in check, it could be a great pick. 
Via The Motley Fool
A Preview Of Viatris's Earnings
 
Via Benzinga
Viatris Stock: Bull vs. Bear
Viatris shares have declined in the double digits over the past few years. 
Via The Motley Fool
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
The analyst illustrated how the dominant force in stock market returns for 2023 has been the "Magnificent 7." 
Via Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
These stocks offer some mouth-watering payouts. 
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Viatris, GSK, and Organon are all trading at less than 7 times earnings. 
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
CVS just fired a shot across Viatris' bow. 
Via The Motley Fool
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
There are a few complicating factors that mean the generic form of the drug might not be a slam dunk. 
Via The Motley Fool
Daily Stock Analysis: Viatris
Viatris Inc’s most recent $0.12 quarterly dividend, paid June 16th to shareholders of record May 23rd, equates to $0.48 annually to throw a yield of 4.58%. 
Via Talk Markets
Better Pharma Buy: Viatris vs. Pfizer
Both stocks look cheap today. 
Via The Motley Fool
Better High-Yield Dividend Stock: Altria or Viatris?
Which of these top income stocks is the better buy right now? 
Via The Motley Fool
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Would you have been better off investing in the S&P 500? 
Via The Motley Fool
Topics Stocks
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Viatris Inc (NASDAQ: VTRS) reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the  
Via Benzinga
Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
If you're patient and consistent, it won't be too hard to build up a revenue stream. 
Via The Motley Fool
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
Unless you're only in it for the dividend, you might be disappointed with this stock. 
Via The Motley Fool
A Look Into Healthcare Sector Value Stocks
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.